Skip to content
Clinical Trials – home

Understanding INSULIN HUMAN (RDNA): A Comprehensive Guide for Patients

0 / 3
trials open to patients / all trials
3+
Countries

In short

This article delves into the use of Insulin Human (rDNA) in clinical trials, focusing on its role in managing diabetes and related conditions. Insulin Human (rDNA) is a synthetic form of insulin that closely mimics the insulin naturally produced by the human body. These trials aim to improve our understanding of how this insulin type can be used more effectively in various patient populations, including those with kidney disease and different gastric emptying rates.

At a glance

Primary Focus
Use of Insulin Human (rDNA) in managing diabetes and related conditions
Patient Groups
Type 1 diabetes, kidney disease patients, individuals with high triglycerides
Key Objectives
Assess insulin sensitivity, optimize blood glucose control, evaluate safety and tolerability
Measurement Methods
Blood glucose levels, insulin sensitivity tests, triglyceride levels, oxidative stress markers
Potential Benefits
Improved glucose control, better management of insulin resistance, reduced complications
Unique Aspects
Consideration of gastric emptying rates, combination with other medications (e.g., statins)

What is INSULIN HUMAN (RDNA)?

INSULIN HUMAN (RDNA), also known as recombinant human insulin, is a synthetic form of insulin produced using genetic engineering techniques. This medication is designed to mimic the insulin naturally produced by the human body. It's important to note that INSULIN HUMAN (RDNA) is also referred to by several other names, including:

  • Insulin, human biosynthetic
  • Insulin human, rDNA
  • Insulin human biosynthetic
  • Insulin human recombinant
  • Insulin human (genetical recombination)

These various names all refer to the same medication, which is a laboratory-created version of human insulin.

Medical Conditions Treated

INSULIN HUMAN (RDNA) is primarily used to treat diabetes mellitus, a condition characterized by high blood sugar levels. It's most commonly used in the treatment of type 1 diabetes, but it can also be used in some cases of type 2 diabetes. In type 1 diabetes, the body doesn't produce insulin, while in type 2 diabetes, the body doesn't use insulin effectively.

Additionally, this medication may be used in the management of insulin resistance, a condition where the body's cells don't respond well to insulin, leading to high blood sugar levels.

How It Works

INSULIN HUMAN (RDNA) works by mimicking the action of natural insulin in the body. Insulin is a hormone that helps regulate blood sugar levels by:

  • Allowing cells in the body to absorb glucose (sugar) from the bloodstream
  • Promoting the storage of excess glucose in the liver and muscles as glycogen
  • Inhibiting the production of glucose by the liver

By performing these functions, INSULIN HUMAN (RDNA) helps to lower blood sugar levels and maintain them within a healthy range.

Administration

INSULIN HUMAN (RDNA) is typically administered via subcutaneous injection or intravenous infusion. The specific dosage and administration schedule will depend on individual patient needs and should be determined by a healthcare professional. It's important to follow the prescribed regimen carefully to maintain optimal blood sugar control.

Potential Side Effects

While INSULIN HUMAN (RDNA) is generally well-tolerated, it can cause side effects in some patients. The most common and serious side effect is hypoglycemia (low blood sugar). Symptoms of hypoglycemia may include:

  • Shakiness
  • Dizziness
  • Sweating
  • Confusion
  • Rapid heartbeat

Other potential side effects may include injection site reactions, allergic reactions, and weight gain. It's important to discuss any side effects with your healthcare provider.

Ongoing Research

Research is ongoing to further understand the effects and optimal use of INSULIN HUMAN (RDNA). Current studies are exploring its use in various contexts:

  • A study is investigating the effect of INSULIN HUMAN (RDNA) on insulin resistance in kidney transplant recipients and patients with chronic kidney disease.
  • Another study is examining the safety and local tolerability of multiple doses of a new insulin formulation in subjects with elevated triglyceride plasma concentrations.
  • Researchers are also comparing the effectiveness of different fast-acting mealtime insulin preparations, including INSULIN HUMAN (RDNA), in individuals with type 1 diabetes who have varying rates of gastric emptying.

Important Considerations

When using INSULIN HUMAN (RDNA), it's crucial to:

  • Regularly monitor your blood sugar levels as directed by your healthcare provider.
  • Be aware of the signs and symptoms of hypoglycemia and how to treat it.
  • Maintain a consistent diet and exercise routine, as changes can affect your insulin needs.
  • Inform all healthcare providers about your insulin use, especially before any surgical procedures.
  • Store the insulin properly according to the manufacturer's instructions.

Always consult with your healthcare provider for personalized advice and guidance on using INSULIN HUMAN (RDNA).

Questions people often ask

Conditions where Insulin Human (Rdna) is being studied

Each condition opens its own overview and trial list

Trials with Insulin Human (Rdna)

Recruiting trials first

See all 3 →
Quick filters
  • Participants:Adults
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).